Concepedia

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

Gavin Giovannoni, F. Casset‐Semanaz, John King, Luanne M. Metz, Gabriel Pardo, James Simsarian, Bettina Stubinski

Multiple Sclerosis Journal · 2008 · 68 citations · 25 references

DOI

Abstract

RNF has improved overall immunogenicity and safety profiles compared with the original formulation.

References

25

Rating neurologic impairment in multiple sclerosis

John F. Kurtzke · Neurology · 1983 · 14.7K citations

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

W. I. McDonald, Alistair Compston, Gilles Edan et al. · Annals of Neurology · 2001 · 6.9K citations

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Daniel D. Mikol, Frederik Barkhof, Peter Chang et al. · The Lancet Neurology · 2008 · 480 citations

, , +8

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Per Soelberg Sørensen, Katja Maria Clemmesen, Klaus Bendtzen et al. · The Lancet · 2003 · 371 citations

, , +12

Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

Katja Maria Clemmesen, Morten Svenson, P. S. S�rensen et al. · Annals of Neurology · 2000 · 224 citations

, , +16